Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Analysis of vascular closure devices after transbrachial artery access.
Mirza AK, Steerman SN, Ahanchi SS, Higgins JA, Mushti S, Panneton JM. Mirza AK, et al. Among authors: mushti s. Vasc Endovascular Surg. 2014 Oct-Nov;48(7-8):466-9. doi: 10.1177/1538574414551576. Epub 2014 Sep 28. Vasc Endovascular Surg. 2014. PMID: 25267690
FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements.
Gandhy SU, Casak SJ, Mushti SL, Cheng J, Subramaniam S, Zhao H, Zhao M, Bi Y, Liu G, Fan J, Adeniyi O, Charlab R, Kufrin D, Thompson MD, Jarrell K, Auth D, Lemery SJ, Pazdur R, Kluetz PG, Fashoyin-Aje LA. Gandhy SU, et al. Among authors: mushti sl. Clin Cancer Res. 2023 Oct 13;29(20):4027-4031. doi: 10.1158/1078-0432.CCR-23-1042. Clin Cancer Res. 2023. PMID: 37289037 Free PMC article.
FDA Approval Summary: Ripretinib for Advanced Gastrointestinal Stromal Tumor.
Kumar V, Doros L, Thompson M, Mushti SL, Charlab R, Spehalski EI, Zhao H, Thompson MD, Tang S, Pazdur R, Lemery SJ, Theoret MR, Fashoyin-Aje LA. Kumar V, et al. Among authors: mushti sl. Clin Cancer Res. 2023 Jun 1;29(11):2020-2024. doi: 10.1158/1078-0432.CCR-22-2400. Clin Cancer Res. 2023. PMID: 36485007 Free PMC article. Clinical Trial.
FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma.
Casak SJ, Marcus L, Fashoyin-Aje L, Mushti SL, Cheng J, Shen YL, Pierce WF, Her L, Goldberg KB, Theoret MR, Kluetz PG, Pazdur R, Lemery SJ. Casak SJ, et al. Among authors: mushti sl. Clin Cancer Res. 2021 Sep 1;27(17):4680-4684. doi: 10.1158/1078-0432.CCR-21-0557. Epub 2021 Apr 12. Clin Cancer Res. 2021. PMID: 33846198 Free PMC article. Clinical Trial.
Benefit-Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine- and Platinum-Based Chemotherapy.
Pelosof L, Saung MT, Donoghue M, Casak S, Mushti S, Cheng J, Jiang X, Liu J, Zhao H, Khazraee M, Goldberg KB, Theoret M, Lemery S, Pazdur R, Fashoyin-Aje L. Pelosof L, et al. Among authors: mushti s. Oncologist. 2021 Apr;26(4):318-324. doi: 10.1002/onco.13646. Epub 2021 Jan 11. Oncologist. 2021. PMID: 33345396 Free PMC article. Clinical Trial.
FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions.
Bradford D, Larkins E, Mushti SL, Rodriguez L, Skinner AM, Helms WS, Price LSL, Zirkelbach JF, Li Y, Liu J, Charlab R, Turcu FR, Liang D, Ghosh S, Roscoe D, Philip R, Zack-Taylor A, Tang S, Kluetz PG, Beaver JA, Pazdur R, Theoret MR, Singh H. Bradford D, et al. Among authors: mushti sl. Clin Cancer Res. 2021 Apr 15;27(8):2130-2135. doi: 10.1158/1078-0432.CCR-20-3558. Epub 2020 Nov 25. Clin Cancer Res. 2021. PMID: 33239432
15 results